🇺🇸 FDA
Patent

US 10087181

Compound as WNT signaling inhibitor, composition, and use thereof

granted A61PA61P1/16A61P11/00

Quick answer

US patent 10087181 (Compound as WNT signaling inhibitor, composition, and use thereof) held by Curegenix, Inc. expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Curegenix, Inc.
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12, A61P17/00